- New spot margin trading pair — CYS/USDT!
- Strong consumer growth + increased usage of AI-powered agent CoCo! Oppenheimer raises price target for Snowflake (SNOW.US) to $400
- Strong consumer growth and increased usage of AI intelligent agent CoCo! Oppenheimer raises Snowflake (SNOW.US) target price to $400
- EPR PROPERTIES <EPR.N>: RAYMOND JAMES RAISES TARGET PRICE TO $65 FROM $60
- PBG board signs off on Q2 2026 results
- OrizonVR buys 51% stake in Rondonópolis sanitary landfill for R$ 45.4 million
- Banrisul cuts 2026 net interest income growth outlook to 5%-10%
- NG Energy reports C$ 26.51 million warrant exercises as unexercised warrants expire
- Avai Bio Q1 FY27 net loss widens 13% to $552,041; revenue remains no revenue
- BRINKER INTERNATIONAL INC <EAT.N>: RAYMOND JAMES RAISES TARGET PRICE TO $270 FROM $210
- POLARYX THERAPEUTICS, INC : RAYMOND JAMES INITIATES COVERAGE WITH STRONG BUY RATING; TARGET PRICE $6
- Nam Cheong 1H FY26 net profit rises 82.9% YoY to RM 164.4 million; revenue climbs 25.2% to RM 348.3 million
- HORACE MANN EDUCATORS CORP <HMN.N>: RAYMOND JAMES RAISES TARGET PRICE TO $59 FROM $53
- APPLIED AEROSPACE & DEFENSE INC : MORGAN STANLEY RAISES TARGET PRICE TO $24.00 FROM $23.00
- CEREBRAS SYSTEMS <CBRS.O>: MORGAN STANLEY RAISES TARGET PRICE TO $279.00 FROM $273.00
- GROCERY OUTLET HOLDING CORP <GO.O>: MORGAN STANLEY RAISES TARGET PRICE TO $11.00 FROM $7.00
- Approaching the 160 red line again! High city government signals support for rate hikes but still can't save the yen, Goldman Sachs says all interventions are “buying time with money.”
- Calian Q3 FY26 revenue hits record as company cites organic growth in Defence & Space, Essential Industries
- Huitianfu Gold and Precious Metals (QDII-LOF-FOF): Suspension of subscription and regular fixed investment services
- Gold LOF: Suspension of subscription and regular fixed investment business, other services remain available as usual
- McGraw Hill FY27 Q1 net income turns to profit at $57.86 million; revenue rises 2.6% to $549.9 million
- EROCK <EROC.N>: BOFA GLOBAL RESEARCH RAISES PRICE OBJECTIVE TO $19.00 FROM $16.00
- Alithya turns to FY27 Q1 net loss of CAD 2.4 million; revenue drops 15.4% to CAD 105.1 million
- Pelthos Therapeutics 2Q Loss/Shr $6.62 >PTHS
- Arcos Dorados FY26 Q2 net income more than doubled to USD 45 million; revenue rises 14.3% to USD 1.31 billion
- Liminatus Pharma moves Nasdaq listing to Capital Market tier
- SES AI appoints Generac engineering executive Paul Diemer to board
- Mobix Labs signs deal to acquire rare earth supply-chain platform Special Project Delivery in all-stock transaction
- Cellectar Biosciences 2Q Loss/Shr 57c >CLRB
- Cellectar Biosciences 2Q Loss $6.93M >CLRB
- STUBHUB HOLDINGS, INC <STUB.N>: BOFA GLOBAL RESEARCH CUTS TO UNDERPERFORM FROM NEUTRAL; CUTS PRICE OBJECTIVE TO $7.5 FROM $11
- FIRST TRACKS BIOTHERAPEUTICS INC <TRAX.O>: WEDBUSH RAISES TARGET PRICE TO $70 FROM $60
- BITGO HOLDINGS INC <BTGO.N>: WEDBUSH CUTS TARGET PRICE TO $8 FROM $15
- Venu Q2 FY26 net loss widens 60% to USD 19.73 million; revenue rises 7% to USD 4.8 million
- CEREBRAS SYSTEMS INC <CBRS.O>: WEDBUSH RAISES TARGET PRICE TO $290 FROM $280
- First Phosphate marks Nasdaq Global Market listing with Aug. 13 opening bell ceremony
- Stock Markets Beware: AI Funding Plans Have -2-
- Stock Markets Beware: AI Funding Plans Have Shades of the Financial Crisis -- Barrons.com
- Pelthos Q2 FY26 net loss narrows to $23.42 million; net product revenue climbs 45% to $15.4 million
- Canada's Quarterhill Q2 revenue dips 1% as tolling activity slows
- 10-Yr Benchmark Govt Yields - Germany vs Other Nations
- 2-Yr Benchmark Govt Yields - Germany vs Other Nations
- 10-Yr Benchmark Govt Yields - U.S. vs Other Nations
- 2-Yr Benchmark Govt Yields - U.S. vs Other Nations
- XCEL ENERGY <XEL.O>: TRUIST SECURITIES CUTS TARGET PRICE TO $88 FROM $94
- MONGODB, INC. <MDB.O>: BOFA GLOBAL RESEARCH RAISES PRICE OBJECTIVE TO $540 FROM $450
- WAYSTAR HOLDING CORP. <WAY.O>: TRUIST SECURITIES CUTS TARGET PRICE TO $33 FROM $38
- Athene publishes fixed income investor presentation highlighting $414B gross invested assets growth
- Banrisul 1H26 net profit falls 11.7% to BRL 547 million
- WEC ENERGY GROUP INC <WEC.N>: TRUIST SECURITIES CUTS TARGET PRICE TO $114 FROM $122
- ADI Global Distribution Sees 2026 Rev $4.950B-$5.000B >ADIG
- Quarterhill 2Q Rev $42.5M >QTRH.T
- Quarterhill 2Q Loss/Shr 5c >QTRH.T
- Tidewater Renewables 2Q EPS C$0.13 >LCFS.T
- Tidewater Renewables 2Q Rev C$160.6M >LCFS.T
- Tidewater Midstream 2Q Net C$15M >TWM.T
- SOUTHERN CO <SO.N>: TRUIST SECURITIES CUTS TARGET PRICE TO $97 FROM $100
- Calian Q3 FY26 adjusted EBITDA climbs 35% to C$26 million; revenue rises 20% to C$230 million
- Chicago Atlantic BDC declares $0.34 per share quarterly cash dividend
- LENZ THERAPEUTICS, INC. <LENZ.O>: BOFA GLOBAL RESEARCH CUTS TO NEUTRAL FROM BUY; CUTS PRICE OBJECTIVE TO $7 FROM $31
- SEPTERNA, INC. <SEPN.O>: TRUIST SECURITIES RAISES TARGET PRICE TO $59 FROM $43
- Lufax Holding to report Q2 2026 results after U.S. market close
- Charlotte's Web Q2 FY26 net loss narrows 34.4% to $4.1 million; revenue falls 15.2% to $10.9 million
- Green Arrow Resources sets Aug. 17 effective date for 1-for-5 share consolidation
- SEMPRA <SRE.N>: TRUIST SECURITIES CUTS TARGET PRICE TO $100 FROM $107
- Herbalife CFO-to-be Schaefer presents at Midwest IDEAS investor conference
- ADI Q2 FY26 net income swings to USD 6 million; net revenue rises 1% year-over-year to USD 1.29 billion
- ADI Global Distribution Sees 2H Rev $2,458B-$2.508B >ADIG
- PSEG : TRUIST SECURITIES CUTS TARGET PRICE TO $84 FROM $90
- Pelthos Therapeutics restates Q1 2026 net loss to USD 25.07 million
- KRATOS DEFENSE & SECURITY SOLUTIONS, INC. <KTOS.O>: TRUIST SECURITIES CUTS TARGET PRICE TO $104 FROM $135
- Lithium Americas releases ESG-S overview fact sheet for Thacker Pass project
- Nouveau Monde Graphite wins amended Quebec decree for Matawinie mine, lifts output cap to 106,000 tonnes
- Athene posts August 2026 fixed income investor presentation on website
- Calian Group 3Q Net C$5.9M >CGY.T
- Calian Group 3Q Rev C$230.4M >CGY.T
- BlackRock lifts Symrise voting rights stake to 8.69% from 8.54%
- ENTERGY <ETR.N>: TRUIST SECURITIES CUTS TARGET PRICE TO $122 FROM $129
- MediWound posts investor presentation on enzymatic burn and chronic-wound therapies NexoBrid, EscharEx
- Asiatic Group appoints Teh Chooi Peng as non-independent non-executive director
- Totm Technologies appoints Alan Ang as growth director, names Gunawan Halim head of product at Totm Labs
- DUCOMMUN INCORPORATED <DCO.N>: TRUIST SECURITIES RAISES TARGET PRICE TO $209 FROM $150
- KP Tissue declares quarterly dividend of $0.21 per share
- Southland amends credit agreement with sureties, cuts interest rate to 4%
- PTC Therapeutics expects FDA BLA filing for ST-920 Fabry gene therapy in Q4 2026
- Diodes plans private placement of USD 325 million convertible senior notes due 2031
- MediWound Q2 FY26 net loss narrows to USD 7.4 million; revenue drops to USD 3.1 million
- DOXIMITY, INC. <DOCS.N>: TRUIST SECURITIES RAISES TARGET PRICE TO $24 FROM $19
- Lithium Americas publishes investor presentation on Thacker Pass Phase 1 construction, path to U.S. lithium production
- POET Technologies 2Q Rev $570,000 >POET
- Olema Pharmaceuticals names Jason O’Byrne CFO
- Pelthos restates Q1 results after ASC 820 error lifts convertible debt fair value by $15.8 million
- Sagimet wins FDA IND clearance for Phase 3 denifanstat acne trial
- Onex 2Q EPS $1.71 >ONEX.T
- Indian Retail F&O Traders Lost $40.36B in 5 Years, With Losses Every Year
- Pyxis Oncology 2Q Research and Development Expenses $16.1M >PYXS
- Pyxis Oncology 2Q Loss/Shr 40c >PYXS
- Rare Evo Conference 2026: Awaiting Clarity & The Agentic Economy Arrives
- Lensar 2Q Net $3.54M >LNSR
- American Shared Hospital 2Q Rev $8.43M >AMS
